Patents by Inventor Benjamin Titz

Benjamin Titz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 11439709
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: September 13, 2022
    Assignee: Cellectar Biosciences, Inc.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
    Publication number: 20180333498
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Application
    Filed: February 12, 2018
    Publication date: November 22, 2018
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Alkylphosphocholine analogs for multiple myeloma imaging and therapy
    Patent number: 9925283
    Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+H3, —N+H2X, —N+HX2, or —N+HX3, wherein each X is independently —CH3 or —C2H5. The compounds can be used to treat multiple myeloma or to detect multiple myeloma. In therapeutic treatment, R1 includes a radionuclide that locally delivers therapeutic dosages of radiation to the multiple myeloma tumors cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radiolabel.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: March 27, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jamey Paul Weichert, Chorom Pak, Benjamin Titz, Fotis Asimakopoulos, Roberta Marino, Mario Otto, Kevin R. Kozak
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9925269
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: March 27, 2018
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9480754
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 1, 2016
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • ALKYLPHOSPHOCHOLINE ANALOGS FOR MULTIPLE MYELOMA IMAGING AND THERAPY
    Publication number: 20160296646
    Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+H3, —N+H2X, —N+HX2, or —N+HX3, wherein each X is independently —CH3 or —C2H5. The compounds can be used to treat multiple myeloma or to detect multiple myeloma. In therapeutic treatment, R1 includes a radionuclide that locally delivers therapeutic dosages of radiation to the multiple myeloma tumors cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radiolabel.
    Type: Application
    Filed: April 11, 2016
    Publication date: October 13, 2016
    Inventors: Jamey Paul Weichert, Chorom Pak, Benjamin Titz, Fotis Asimakopoulos, Roberta Marino, Mario Otto, Kevin R. Kozak
  • Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
    Publication number: 20160228564
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9345718
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 24, 2016
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
    Publication number: 20160136190
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 19, 2016
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
    Publication number: 20160136290
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 19, 2016
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle